

Product Data Sheet

Product Name: PROTAC SKP2 Degradator-1

Cat. No.: GC81026

Chemical Properties

Cas. No. 3120650-15-6


Formula $C_{60}H_{91}N_5O_{10}S$ M.Wt 1074.46

Solubility DMSO: 100 mg/mL (93.07 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

PROTAC SKP2 Degradator-1 is a PROTAC degrader targeting SKP2, with a K_d value of 6.28 μ M. PROTAC SKP2 Degradator-1 induces targeted degradation of SKP2 via the ubiquitin-proteasome system. PROTAC SKP2 Degradator-1 stabilizes the expression of SOCS1 and regulates the

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

expression of immunoproteasomes through the JAK/STAT pathway, thereby inhibiting tumor cell proliferation. PROTAC SKP2 Degradar-1 is applicable for cancer-related research^[1]. (Pink: Skp2 ligand; Blue: VHL ligand; Black: linker).

In Vivo, PROTAC SKP2 Degradar-1 (10-40 mg/kg; i.p.; daily; 14 days) dose-dependently inhibits subcutaneous Jurkat xenograft tumor growth in female NCG mice^[1].

In Vitro, PROTAC SKP2 Degradar-1 (compound HD15) (48 h) inhibits the proliferation of Jurkat cells with an IC₅₀ value of 0.98 μ M^[1]. PROTAC SKP2 Degradar-1 (0.0625-1 μ M; 48 h) induces proteasome-dependent degradation of SKP2 in Jurkat cells, with a DC₅₀ of 0.29 μ M^[1]. PROTAC SKP2 Degradar-1 (0.0625-1 μ M; 48 h) modulates the SOCS1/JAK/STAT1/immunoproteasome axis in Jurkat cells, upregulates SOCS1, inhibits p-STAT1, and downregulates the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in a concentration-dependent manner^[1]. PROTAC SKP2 Degradar-1 (0-6 μ M; 48 h) inhibits DNA synthesis and proliferation in Jurkat and Hut78 cells in a dose-dependent manner^[1]. PROTAC SKP2 Degradar-1 (0.1875-6 μ M; 48 h) induces apoptosis in Jurkat cells in a dose-dependent manner^[1].

References:

[1]. Chen L, et al. Natural Product-Inspired PROTACs for Leukemia Therapy: Hederagenin-Driven Targeted Degradation of SKP2. J Med Chem. 2026;69(4):4579-4601.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA